PledPharma AB (publ) Share Price Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
Sales 2024 * | 68.03M 6.35M 501M | Sales 2025 * | 514M 48.02M 3.79B | Capitalization | 1.99B 185M 14.64B |
---|---|---|---|---|---|
Net income 2024 * | -269M -25.11M -1.98B | Net income 2025 * | 125M 11.67M 921M | EV / Sales 2024 * | 24.2 x |
Net cash position 2024 * | 341M 31.87M 2.52B | Net cash position 2025 * | 226M 21.06M 1.66B | EV / Sales 2025 * | 3.42 x |
P/E ratio 2024 * |
-8.15
x | P/E ratio 2025 * |
12.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.61% |
Latest transcript on PledPharma AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 15/06/17 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 45 | 30/12/17 |
Chief Tech/Sci/R&D Officer | - | 04/05/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mats Blom
CHM | Chairman | 59 | 31/03/21 |
Director/Board Member | 50 | 31/12/19 | |
Thomas Lönngren
BRD | Director/Board Member | 73 | 31/03/21 |
1st Jan change | Capi. | |
---|---|---|
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |